WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS
Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher, but started falling when investors realized that sales will drop next quarter. Our negative stance on Ampyra sales has proven right. Earlier in the year,